Symbols / ICU Stock $4.13 -2.59% SeaStar Medical Holding Corporation

Healthcare • Biotechnology • United States • NCM
ICU (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Eric Schlorff
Exch · Country NCM · United States
Market Cap 16.49M
Enterprise Value 5.04M
Income -12.15M
Sales 1.23M
FCF (ttm) -9.39M
Book/sh 2.71
Cash/sh 3.00
Employees 17
Insider 10d —
IPO Mar 18, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.61
PEG —
P/S 13.37
P/B 1.52
P/C —
EV/EBITDA —
EV/Sales 4.08
Quick Ratio 3.27
Current Ratio 3.63
Debt/Eq 5.04
LT Debt/Eq —
EPS (ttm) -5.86
EPS next Y -2.57
EPS Growth —
Revenue Growth 5.27%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-25
Earnings (prior) 2026-03-25
ROA -80.88%
ROE -295.15%
ROIC —
Gross Margin 95.70%
Oper. Margin -7.18%
Profit Margin 0.00%
Shs Outstand 3.99M
Shs Float 3.95M
Insider Own 2.40%
Instit Own 6.10%
Short Float 4.02%
Short Ratio 0.63
Short Interest 159.38K
52W High 13.40
vs 52W High -69.18%
52W Low 2.07
vs 52W Low 99.52%
Beta -1.19
Impl. Vol. —
Rel Volume 0.92
Avg Volume 145.32K
Volume 133.94K
Target (mean) $9.00
Tgt Median $9.00
Tgt Low $6.00
Tgt High $12.00
# Analysts 2
Recom None
Prev Close $4.24
Price $4.13
Change -2.59%
About

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.00
Mean price target
2. Current target
$4.13
Latest analyst target
3. DCF / Fair value
$-42.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.13
Low
$6.00
High
$12.00
Mean
$9.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-04-20 init Maxim Group — → Buy $5
News
RSS: Latest ICU news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-19 BAIRD JENNIFER A Director — 4,200 $0.24 $987
2025-12-09 MESSINGER MICHAEL Chief Financial Officer — 14,500 $0.35 $5,098
2025-08-27 VAN HEEL KENNETH J. Director — 35,000 $0.86 $30,812
2025-08-22 CHUNG KEVIN Officer — 10,000 $0.80 $8,000
2025-07-10 VAN HEEL KENNETH J. Director — 4,000 — —
2025-07-10 NEUMAN JOHN Director — 4,000 — —
2025-07-10 BAIRD JENNIFER A Director — 4,000 — —
2025-07-10 VINCENT BERNADETTE N Director — 4,000 — —
2025-07-01 SCHLORFF ERIC Chief Executive Officer — 21,667 — —
2025-07-01 CHUNG KEVIN Officer — 5,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.23
+814.07%
0.14
0.00
0.00
Operating Revenue
1.23
+814.07%
0.14
0.00
0.00
Cost Of Revenue
0.05
0.00
0.00
—
Reconciled Cost Of Revenue
0.05
0.00
0.00
—
Gross Profit
1.18
+774.81%
0.14
0.00
—
Operating Expense
13.36
-25.71%
17.98
+26.51%
14.21
+22.41%
11.61
Research And Development
7.52
-17.43%
9.11
+52.44%
5.97
+138.63%
2.50
Selling General And Administration
5.84
-34.20%
8.87
+7.71%
8.24
+19.10%
6.92
General And Administrative Expense
5.84
-34.20%
8.87
+7.71%
8.24
+19.10%
6.92
Other Gand A
5.84
-34.20%
8.87
+7.71%
8.24
+19.10%
6.92
Other Operating Expenses
—
—
—
2.19
Total Expenses
13.41
-25.41%
17.98
+26.51%
14.21
+22.41%
11.61
Operating Income
-12.18
+31.76%
-17.84
-25.56%
-14.21
-22.41%
-11.61
Total Operating Income As Reported
-12.18
+31.76%
-17.84
-25.56%
-14.21
-22.41%
-11.61
EBITDA
-12.12
+50.71%
-24.58
+2.26%
-25.15
-117.59%
-11.56
Normalized EBITDA
-12.15
+49.14%
-23.89
-22.88%
-19.44
-67.45%
-11.61
EBIT
-12.12
+50.71%
-24.58
+2.26%
-25.15
-117.59%
-11.56
Total Unusual Items
0.03
+104.59%
-0.70
+87.80%
-5.71
-11524.00%
0.05
Total Unusual Items Excluding Goodwill
0.03
+104.59%
-0.70
+87.80%
-5.71
-11524.00%
0.05
Special Income Charges
—
0.00
+100.00%
-4.95
0.00
Other Special Charges
—
—
4.95
—
Net Income
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Pretax Income
-12.15
+51.07%
-24.83
+5.36%
-26.23
-115.21%
-12.19
Net Non Operating Interest Income Expense
-0.00
+97.20%
-0.14
+86.77%
-1.08
-71.59%
-0.63
Interest Expense Non Operating
0.03
-87.30%
0.24
-77.43%
1.08
+71.59%
0.63
Net Interest Income
-0.00
+97.20%
-0.14
+86.77%
-1.08
-71.59%
-0.63
Interest Expense
0.03
-87.30%
0.24
-77.43%
1.08
+71.59%
0.63
Interest Income Non Operating
0.33
+221.78%
0.10
0.00
—
Interest Income
0.33
+221.78%
0.10
0.00
—
Other Income Expense
0.03
+100.47%
-6.84
+37.46%
-10.94
-21982.00%
0.05
Other Non Operating Income Expenses
—
-6.14
-17.52%
-5.23
—
Gain On Sale Of Security
0.03
+104.59%
-0.70
+8.65%
-0.76
-1626.00%
0.05
Tax Provision
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.01
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Net Income From Continuing Operation Net Minority Interest
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Net Income From Continuing And Discontinued Operation
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Net Income Continuous Operations
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Normalized Income
-12.18
+49.55%
-24.13
-17.61%
-20.52
-67.65%
-12.24
Net Income Common Stockholders
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Diluted EPS
—
-66.33
+78.08%
-302.60
+56.77%
-700.00
Basic EPS
—
-66.33
+78.08%
-302.60
+56.77%
-700.00
Basic Average Shares
—
0.37
+331.88%
0.09
+163.91%
0.03
Diluted Average Shares
—
0.37
+331.88%
0.09
+163.91%
0.03
Diluted NI Availto Com Stockholders
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Gain On Sale Of PPE
—
—
—
—
Total Other Finance Cost
0.30
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
14.16
+203.95%
4.66
+32.59%
3.51
+15.64%
3.04
Current Assets
13.58
+260.59%
3.77
+63.17%
2.31
+51.94%
1.52
Cash Cash Equivalents And Short Term Investments
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Cash And Cash Equivalents
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Cash Financial
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Receivables
0.24
+111.61%
0.11
0.00
-100.00%
0.01
Accounts Receivable
0.24
+111.61%
0.11
0.00
—
Gross Accounts Receivable
0.24
+114.29%
0.11
—
—
Allowance For Doubtful Accounts Receivable
-0.00
0.00
—
—
Other Receivables
—
—
—
0.01
Inventory
0.07
0.00
—
—
Prepaid Assets
1.30
-29.32%
1.83
-13.93%
2.13
+46.03%
1.46
Total Non Current Assets
0.58
-35.20%
0.89
-25.98%
1.21
-20.67%
1.52
Other Non Current Assets
0.58
-35.20%
0.89
-25.98%
1.21
-20.67%
1.52
Total Liabilities Net Minority Interest
3.74
-45.30%
6.84
-60.65%
17.38
-26.96%
23.80
Current Liabilities
3.74
-45.30%
6.84
-47.56%
13.05
-19.21%
16.15
Payables And Accrued Expenses
3.22
-48.41%
6.23
+5.75%
5.89
+41.30%
4.17
Payables
0.95
-68.88%
3.05
-30.33%
4.37
+126.88%
1.93
Accounts Payable
0.95
-68.88%
3.05
-30.33%
4.37
+126.88%
1.93
Current Accrued Expenses
2.27
-28.86%
3.19
+109.32%
1.52
-32.16%
2.25
Current Debt And Capital Lease Obligation
0.53
-8.54%
0.57
-87.90%
4.74
+302.72%
1.18
Current Debt
0.53
-8.54%
0.57
-87.90%
4.74
+302.72%
1.18
Other Current Borrowings
0.53
-8.54%
0.57
-87.90%
4.74
+302.72%
1.18
Current Deferred Liabilities
—
0.00
-100.00%
0.10
—
Current Deferred Revenue
—
0.00
-100.00%
0.10
—
Other Current Liabilities
0.00
-96.97%
0.03
-98.57%
2.31
-78.63%
10.80
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
4.34
-43.32%
7.65
Long Term Debt And Capital Lease Obligation
—
—
4.34
-43.32%
7.65
Long Term Debt
—
—
4.34
-43.32%
7.65
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Common Stock Equity
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Capital Stock
0.00
+100.00%
0.00
+100.00%
0.00
+0.00%
0.00
Common Stock
0.00
+100.00%
0.00
+100.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.84
+543.21%
0.60
+213.83%
0.19
+274.94%
0.05
Ordinary Shares Number
3.84
+543.21%
0.60
+213.83%
0.19
+274.94%
0.05
Additional Paid In Capital
162.13
+18.01%
137.38
+36.20%
100.86
+48.90%
67.74
Retained Earnings
-151.71
-8.71%
-139.56
-21.64%
-114.73
-29.64%
-88.50
Total Equity Gross Minority Interest
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Total Capitalization
10.42
+577.14%
-2.18
+77.10%
-9.53
+27.28%
-13.11
Working Capital
9.84
+419.93%
-3.08
+71.36%
-10.74
+26.60%
-14.63
Invested Capital
10.94
+779.99%
-1.61
+66.40%
-4.79
+59.86%
-11.93
Total Debt
0.53
-8.54%
0.57
-93.68%
9.08
+2.84%
8.83
Net Debt
—
—
8.90
+1.39%
8.78
Net Tangible Assets
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Tangible Book Value
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Current Notes Payable
—
—
—
1.18
Derivative Product Liabilities
—
—
—
0.00
Financial Assets
—
—
—
1.73
Interest Payable
—
—
0.02
-83.04%
0.11
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.60
+15.04%
-16.01
-55.63%
-10.29
-31.96%
-7.79
Cash Flow From Continuing Operating Activities
-13.60
+15.04%
-16.01
-55.63%
-10.29
-31.96%
-7.79
Net Income From Continuing Operations
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Other Non Cash Items
0.32
+209.80%
0.10
+112.50%
0.05
-91.77%
0.58
Stock Based Compensation
0.62
-29.65%
0.89
-54.04%
1.93
+47.22%
1.31
Operating Gains Losses
-0.03
-104.59%
0.70
-87.80%
5.71
+11524.00%
-0.05
Gain Loss On Investment Securities
-0.03
-104.59%
0.70
-8.65%
0.76
+1626.00%
-0.05
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
6.14
+14.22%
5.38
0.00
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-2.36
-337.60%
0.99
-65.52%
2.88
+12.74%
2.55
Change In Receivables
-0.12
-11.61%
-0.11
-1033.33%
0.01
+200.00%
0.00
Changes In Account Receivables
-0.12
-11.61%
-0.11
0.00
—
Change In Inventory
-0.07
0.00
—
0.00
Change In Prepaid Assets
0.54
+81.14%
0.30
+406.19%
-0.10
+90.96%
-1.07
Change In Payables And Accrued Expense
-3.02
-608.08%
0.59
-79.95%
2.96
-18.20%
3.62
Change In Accrued Expense
-0.92
-149.07%
1.88
+262.67%
0.52
-75.06%
2.07
Change In Payable
-2.10
-63.78%
-1.28
-152.39%
2.44
+57.95%
1.55
Change In Account Payable
-2.10
-63.78%
-1.28
-152.39%
2.44
+57.95%
1.55
Change In Other Current Assets
0.31
+0.32%
0.31
0.00
—
Change In Other Current Liabilities
0.00
+100.00%
-0.10
0.00
—
Financing Cash Flow
23.76
+34.62%
17.65
+69.48%
10.41
+42.05%
7.33
Cash Flow From Continuing Financing Activities
23.76
+34.62%
17.65
+69.48%
10.41
+42.05%
7.33
Net Issuance Payments Of Debt
-0.07
+98.48%
-4.41
-224.93%
3.53
+1.41%
3.48
Issuance Of Debt
0.77
-54.67%
1.69
-80.77%
8.80
+147.26%
3.56
Repayment Of Debt
-0.83
+86.33%
-6.10
-15.79%
-5.27
-6656.41%
-0.08
Long Term Debt Issuance
0.77
-54.67%
1.69
-80.77%
8.80
+147.26%
3.56
Long Term Debt Payments
-0.83
+86.33%
-6.10
-15.79%
-5.27
-6656.41%
-0.08
Net Long Term Debt Issuance
-0.07
+98.48%
-4.41
-224.93%
3.53
+1.41%
3.48
Net Common Stock Issuance
16.13
-7.54%
17.44
+163.78%
6.61
-33.89%
10.00
Proceeds From Stock Option Exercised
7.70
+66.72%
4.62
+498.32%
0.77
+115.63%
-4.94
Net Other Financing Charges
—
—
-0.50
+58.71%
-1.21
Changes In Cash
10.16
+518.44%
1.64
+1173.64%
0.13
+127.86%
-0.46
Beginning Cash Position
1.82
+933.52%
0.18
+274.47%
0.05
-90.78%
0.51
End Cash Position
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Free Cash Flow
-13.60
+15.04%
-16.01
-55.63%
-10.29
-31.96%
-7.79
Interest Paid Supplemental Data
0.00
-100.00%
0.55
-50.89%
1.13
+18666.67%
0.01
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Common Stock Issuance
16.13
-7.54%
17.44
+163.78%
6.61
-33.89%
10.00
Issuance Of Capital Stock
16.13
-7.54%
17.44
+163.78%
6.61
-33.89%
10.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category